Cardiol hits MAVERIC enrollment target early, expands trial to 150 patientsSep 23Clinical readoutCardiol Therapeutics Inc.
Cardiol's Phase II pericarditis data published in JAHA as Phase III MAVERIC nears full enrollmentJul 14Clinical readoutCardiol Therapeutics Inc.pharmaceutically produced cannabidiol
Sign inSign in